Johnson & Johnson (JNJ) Research & Development (2009 - 2026)
Johnson & Johnson (JNJ) posted Research & Development of $3.7 billion for Q2 2026, up 3.57% sequentially from $3.5 billion in Q1 2026, and up 3.9% YoY from $3.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Research & Development (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Research & Development for 18 years, with the latest figure at $3.7 billion in Q2 2026.
- Quarterly Research & Development rose 3.9% year-over-year to $3.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.1 billion (down 11.11% YoY) and the FY2025 annual result came in at $14.7 billion, down 14.9% from the prior year.
- Research & Development improved to $3.7 billion in Q2 2026 per JNJ's latest filing, from $3.5 billion in the prior quarter.
- Over five years, Research & Development peaked at $6.2 billion in Q1 2022 and troughed at $3.2 billion in Q1 2025.
- A 5-year average of $4.0 billion and a median of $3.7 billion in 2026 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development plunged 32.67% in 2023, then surged 43.66% in 2024.
- Over 5 years, Research & Development stood at $3.5 billion in 2022, then advanced by 28.55% to $4.5 billion in 2023, then advanced by 18.26% to $5.3 billion in 2024, then retreated by 19.74% to $4.3 billion in 2025, then dropped by 14.09% to $3.7 billion in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.7 billion, $3.5 billion, and $4.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 3.65 Bn |
| Mar 29, 2026 | 3.53 Bn |
| Dec 28, 2025 | 4.25 Bn |
| Sep 28, 2025 | 3.67 Bn |
| Jun 29, 2025 | 3.52 Bn |
| Mar 30, 2025 | 3.23 Bn |
| Dec 29, 2024 | 5.30 Bn |
| Sep 29, 2024 | 4.95 Bn |
| Jun 30, 2024 | 3.44 Bn |
| Mar 31, 2024 | 3.54 Bn |
| Dec 31, 2023 | 4.48 Bn |
| Oct 1, 2023 | 3.45 Bn |
| Jul 2, 2023 | 3.70 Bn |
| Apr 2, 2023 | 3.46 Bn |
| Jan 1, 2023 | 4.14 Bn |
| Oct 2, 2022 | 3.49 Bn |
| Jul 3, 2022 | 3.70 Bn |
| Apr 3, 2022 | 3.46 Bn |
| Jan 2, 2022 | 6.15 Bn |
| Oct 3, 2021 | 3.42 Bn |